Product

Belgium approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, February 12, 2014 - Sandoz announced it has received marketing authorization in Belgium for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013 with subsequent marketing authorizations received in Germany, Sweden, Hungary, Romania, Bulgaria, and Norway.

The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Norway approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, February 10, 2014 - Sandoz announced today it has received Norwegian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Sweden, Hungary, Romania and Bulgaria.

The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Sandoz launches Kerdyn TM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc.

Princeton, New Jersey, September 22, 2014 - Sandoz, through its branded dermatology business, PharmaDerm, today announced the US launch of KERYDINTM (tavaborole) topical solution, 5%, developed  by Anacor Pharmaceuticals, Inc.

In July 2014, Sandoz announced an agreement with Anacor Pharmaceuticals, Inc. to obtain exclusive rights to commercialize KERYDINTM in the US.

Sandoz launches the first generic version of Hectorol®

Princeton, New Jersey, February 5, 2014 - Sandoz today announced the US launch of doxercalciferol injection vials, the first generic version of Genzyme's Hectorol®.

Doxercalciferol injection vials are indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.1

"Sandoz is pleased to be the first company to market a high quality, affordable generic version of this important product to dialysis patients in the US," said Peter Goldschmidt, President of Sandoz Inc.

Sandoz launches ready-to-use oral formulation of ACC® cough medicine in Ukraine

  • Sandoz launches new ready to use oral formulation of ACC® in the Ukrainian market
  • ACC® oral solution is used for children from 2 years old
  • New form has cherry flavor and is available with convenient dispenser

Kiev, November 12, 2014 – Sandoz, the generic pharmaceutical division of Novartis, today announces the launch in Ukraine of a new ready-to-use oral formulation of ACC® cough medicine.

South Korea approves AirFluSal® Forspiro®

Munich, Germany, February 28, 2014 - Sandoz announced today it has received South Korean marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD, marking its first approval in Asia.

The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania and Bulgaria.

Romania approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, January 29, 2014 - Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Subscribe to RSS - Product